↓
 

Hepatitis B @HCVAdvocate

Hepatitis B @HCVAdvocate
  • Home
  • Sample Page

Category Archives: entecavir

Post navigation

← Older posts

Generic Entecavir Hepatitis B Treatment Approved

Hepatitis B @HCVAdvocate Posted on September 2, 2015 by hcv_p4r4nk59September 2, 2015  

A generic equivalent to Bristol-Myers Squibb’s entecavir (Baraclude) hepatitis B treatment has been approved by the FDA. Aurobindo Pharma’s generic entecavir will soon be available in 0.5 mg and 1 mg oral tablet strengths. Entecavir is a nucleoside analogue indicated … Continue reading →

Posted in entecavir, generic Baraclude, generic entecavir, hbv treatment, treatment, treatment costs | Leave a reply

Long-term entecavir, TDF effective in chronic HBV in real-world setting

Hepatitis B @HCVAdvocate Posted on March 13, 2015 by HCV AdvocateMarch 13, 2015  

A Turkish clinical practice study shows that entecavir and tenofovir disoproxil fumarate (TDF) can effectively maintain long-term virological and biochemical responses in patients with chronic hepatitis B virus (HBV) infection, both in those with and without cirrhosis. Hepatocellular carcinoma (HCC) … Continue reading →

Posted in entecavir, long-term suppression, tenofovir | Leave a reply

Entecavir Cuts Hep B Reactivation in Diffuse Large B-Cell Lymphoma

Hepatitis B @HCVAdvocate Posted on December 17, 2014 by HCV AdvocateDecember 17, 2014  

TUESDAY, Dec. 16, 2014 (HealthDay News) — Entecavir is more efficacious than lamivudine for preventing hepatitis B virus (HBV) reactivation among patients who are seropositive for the hepatitis B surface antigen with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, … Continue reading →

Posted in B-Cell Lymphoma, entecavir, HBV Reactivation | Leave a reply

Entecavir and Tenofovir Equally Effective in HBeAg-positive Patients and Cirrhotics

Hepatitis B @HCVAdvocate Posted on December 4, 2014 by HCV AdvocateDecember 4, 2014  

— Christine M. Kukka, Project Manager, HBV Advocate A four-year study of 355 patients treated with either tenofovir (Viread) or entecavir (Baraclude) found both antivirals to be highly effective in reducing viral loads, according to a report published in the … Continue reading →

Posted in entecavir, tenofovir, treatment efficacy | Leave a reply

Post navigation

← Older posts

Search this Site

Share This SIte

Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow HCV Advocate

Facebooktwitter

Subscribe to our mailing list



Check Out Our Other Sites

  • Home (HBV Advocate Blog)
  • HBV Advocate
  • HCV Advocate
  • Hepatitis & Tattoos
  • Tattoo Blog
  • HCV Advocate News & Pipeline Blog

Archives

  • May 2017 (2)
  • April 2017 (3)
  • March 2017 (4)
  • February 2017 (3)
  • January 2017 (5)
  • December 2016 (1)
  • November 2016 (11)
  • October 2016 (6)
  • September 2016 (2)
  • August 2016 (3)
  • July 2016 (12)
  • June 2016 (6)
  • April 2016 (2)
  • March 2016 (3)
  • February 2016 (3)
  • January 2016 (7)
  • December 2015 (7)
  • November 2015 (11)
  • October 2015 (10)
  • September 2015 (12)
  • August 2015 (10)
  • July 2015 (13)
  • June 2015 (15)
  • May 2015 (10)
  • April 2015 (30)
  • March 2015 (15)
  • February 2015 (25)
  • January 2015 (25)
  • December 2014 (18)
  • November 2014 (23)
  • October 2014 (13)
  • September 2014 (18)
  • August 2014 (17)
  • July 2014 (32)
  • June 2014 (20)
  • May 2014 (29)
  • April 2014 (36)
  • March 2014 (28)
  • February 2014 (29)
  • January 2014 (11)
  • December 2013 (19)
  • November 2013 (26)
  • October 2013 (20)
  • September 2013 (23)
  • August 2013 (25)
  • July 2013 (31)
  • June 2013 (26)
© 2015 HCVAdvocate.org

Top of Blog    

↑